补充益生菌治疗双相抑郁症的安全性和有效性 (ALIGN)
益生菌补充剂对双相抑郁症的安全性和有效性:概念验证随机对照试验
这是一项为期 8 周的随机、双盲、安慰剂对照的概念验证研究,评估情绪稳定剂 + Align 联合治疗双相抑郁发作的参与者。 该研究有两个治疗组:情绪稳定剂加安慰剂和情绪稳定剂加 Align。
情绪稳定剂的剂量将符合临床实践指南,Align 的剂量将根据适当的产品剂量每天 1 粒胶囊。
研究概览
详细说明
抑郁症已成为双相情感障碍短期和长期管理的主要挑战;需要新的治疗方法来帮助控制这种疾病。 研究表明,胃中的益生菌可以改善情绪并减少焦虑症状,进一步支持益生菌对情绪状态产生积极影响的观点。 我们建议评估情绪稳定剂与益生菌 Align 联合治疗与情绪稳定剂单一疗法相比的有效性。
这项可行性研究的主要目标是确定 Align 作为 BD 中公认的单一疗法治疗的补充的安全性和耐受性。 次要目标:1) 与情绪稳定剂单一疗法相比,评估情绪稳定剂 + Align 联合治疗 BD 的有效性。 2) 确定 Align + 情绪稳定剂组合是否会减轻焦虑症状。
一项为期 8 周的随机、双盲、安慰剂对照的概念验证研究,评估情绪稳定剂 + Align 联合治疗双相抑郁发作患者的效果。 该研究有两个治疗组:情绪稳定剂 + 安慰剂和情绪稳定剂 + Align。 将在筛选、基线和第 2、4、6 和 8 周时对参与者进行评估和管理研究量表。情绪稳定剂的剂量将根据临床实践指南和 Align - 1 粒胶囊/天。
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G1N8
- Women's College Research Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
纳入标准:
- 了解研究的性质并同意并能够阅读、审查和签署知情同意书。 知情同意书将以英文书写,因此志愿者必须具备英文阅读和交流能力
- 筛选时年龄在 18 至 65 岁之间的男性和女性参与者
- 根据 Mini International Neuropsychiatric interview (MINI) 证明诊断为双相抑郁症(I 型或 II 型)
- 筛选时未住院或住院(门诊)
- 在筛选前至少 8 周一直服用稳定(未改变)且足够剂量的一种允许药物(锂盐、丙戊酸盐/双丙戊酸盐、卡马西平、拉莫三嗪、喹硫平/喹硫平缓释片、奥氮平或利培酮)
- 在筛选和基线访问时显示最高 HAM-D 分数为 24
- 女性参与者必须:
不是母乳喂养 在本研究过程中未怀孕或未寻求怀孕。 绝经或使用可接受的节育方法(植入物、注射剂、复方口服避孕药、宫内节育器、性禁欲或输精管切除术的伴侣)
排除标准:
- 展示或报告过去一年中任何 DSM-IV 物质滥用/依赖障碍分类标准的历史记录。
- 证明存在主动进食障碍、精神分裂症或分裂情感障碍
- 表现出当前的精神病症状
- 在筛选时表现出 Young Mania Rating Scale (YMRS) 得分 >12
- 基于 C-SSR 量表表现出主动自杀倾向
- 筛选前 14 天内使用任何强效细胞色素 P450 抑制剂(如氯霉素、抗真菌剂)的报告
- 报告筛选前 90 天内的电休克疗法 (ECT) 史
- 在筛选前的最后一年内使用 Align 或任何其他益生菌补充剂的报告
- 报告对 Align 成分(如双歧杆菌)或任何其他相关药物的过敏反应史。
- 报告可能影响药物药代动力学的任何医疗状况(胃肠道状况,如肠胃炎或结肠炎)的存在或病史。
- 报告任何免疫妥协病史(如 HIV、淋巴瘤、接受长期皮质类固醇治疗的患者)
- 目前正在经历恶心、发烧、呕吐、血性腹泻或严重腹痛
- 报告在筛选前的最后 6 个月内使用过影响抑郁症的其他天然保健品(除益生菌外)(如圣约翰疣、色氨酸)
- 报告经常食用富含/富含益生菌的食物(例如 酸奶、饮料等)。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
安慰剂比较:安慰剂
每天一次安慰剂胶囊
|
安慰剂胶囊
|
有源比较器:婴儿双歧杆菌
婴儿双歧杆菌 (Align) 1000 万 cfu 胶囊,每日一次
|
益生菌补充剂
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Align 的安全性和耐受性
大体时间:8周
|
将使用 Toronto Side Effect Scale (TSES) 评估耐受性。
它是一个包含 32 项的工具,旨在确定中枢神经系统 (CNS)、胃肠道 (GI) 和性副作用的发生率、频率和严重程度。
我们还将评估因抑郁症状控制不当或治疗突发躁狂症而退出研究的参与者比例
|
8周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
情绪稳定剂+Align组合的功效
大体时间:8周
|
这将通过从基线到最终访问(第 8 周)的蒙哥马利-奥斯伯格抑郁量表 (MADRS) 总分的变化来评估
|
8周
|
在焦虑症状和整体功能/整体改善方面,评估双相抑郁症参与者与情绪稳定剂单一疗法相比,情绪稳定剂 + Align 的组合
大体时间:8周
|
将通过查看状态和特质焦虑指数 (STAI) 总分的平均变化来评估焦虑症状,将使用世界卫生组织生活质量 (WHO-QOL) 量表评估生活质量,并访问全球功能通过以下各项的平均变化:希恩残疾量表 (SDS) 评分、临床总体印象 (CGI) 疾病严重程度评分、CGI 改善量表和 CGI 参与者评估。
将评估所有措施,看看从基线到第 8 周的变化
|
8周
|
合作者和调查者
调查人员
- 首席研究员:Valerie Taylor, PhD、Women's College Hospital
出版物和有用的链接
一般刊物
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
- O'Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry. 2009 Feb 1;65(3):263-7. doi: 10.1016/j.biopsych.2008.06.026. Epub 2008 Aug 23.
- Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004 Mar;13(2):299-310. doi: 10.1023/B:QURE.0000018486.91360.00.
- Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16050-5. doi: 10.1073/pnas.1102999108. Epub 2011 Aug 29.
- Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008 Dec;43(2):164-74. doi: 10.1016/j.jpsychires.2008.03.009. Epub 2008 May 5.
- Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010 Nov 10;170(4):1179-88. doi: 10.1016/j.neuroscience.2010.08.005. Epub 2010 Aug 6.
- Li W, Dowd SE, Scurlock B, Acosta-Martinez V, Lyte M. Memory and learning behavior in mice is temporally associated with diet-induced alterations in gut bacteria. Physiol Behav. 2009 Mar 23;96(4-5):557-67. doi: 10.1016/j.physbeh.2008.12.004. Epub 2008 Dec 24.
- Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3047-52. doi: 10.1073/pnas.1010529108. Epub 2011 Jan 31.
- Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009 Aug;116(3):214-7. doi: 10.1016/j.jad.2008.12.001. Epub 2009 Feb 28.
- Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord. 2010 Nov;126(3):458-62. doi: 10.1016/j.jad.2010.04.027.
- Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011 Mar;23(3):255-64, e119. doi: 10.1111/j.1365-2982.2010.01620.x. Epub 2010 Nov 5.
- Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009 Mar 19;1(1):6. doi: 10.1186/1757-4749-1-6.
- Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses. 2005;64(3):533-8. doi: 10.1016/j.mehy.2004.08.019.
- Girard SA, Bah TM, Kaloustian S, Lada-Moldovan L, Rondeau I, Tompkins TA, Godbout R, Rousseau G. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br J Nutr. 2009 Nov;102(10):1420-5. doi: 10.1017/S0007114509990766. Epub 2009 Jun 29.
- Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med. 2005 Jan;257(1):78-92. doi: 10.1111/j.1365-2796.2004.01410.x.
- Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut. 2007 Nov;56(11):1522-8. doi: 10.1136/gut.2006.117176. Epub 2007 Mar 5. Erratum In: Gut. 2008 Apr;57(4):560.
- Eutamene H, Bueno L. Role of probiotics in correcting abnormalities of colonic flora induced by stress. Gut. 2007 Nov;56(11):1495-7. doi: 10.1136/gut.2007.124040.
- Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol. 2006 Mar;40(3):264-9. doi: 10.1097/00004836-200603000-00020.
- Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002 Jun;59(6):530-7. doi: 10.1001/archpsyc.59.6.530.
- Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011 Mar;23(3):187-92. doi: 10.1111/j.1365-2982.2010.01664.x.
- Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun. 2010 Jan;24(1):9-16. doi: 10.1016/j.bbi.2009.05.058. Epub 2009 May 28.
- Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009 May;6(5):306-14. doi: 10.1038/nrgastro.2009.35.
- Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004 Jul 1;558(Pt 1):263-75. doi: 10.1113/jphysiol.2004.063388. Epub 2004 May 7.
- Goehler LE, Gaykema RP, Opitz N, Reddaway R, Badr N, Lyte M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni. Brain Behav Immun. 2005 Jul;19(4):334-44. doi: 10.1016/j.bbi.2004.09.002.
- Lyte M, Li W, Opitz N, Gaykema RP, Goehler LE. Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium. Physiol Behav. 2006 Oct 30;89(3):350-7. doi: 10.1016/j.physbeh.2006.06.019. Epub 2006 Aug 2.
- Kunz M, Cereser KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-Sant'Anna M, Kapczinski F, Gama CS. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Braz J Psychiatry. 2011 Sep;33(3):268-74. doi: 10.1590/s1516-44462011000300010.
- Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009 May;12(4):447-58. doi: 10.1017/S1461145708009310. Epub 2008 Sep 4.
- Padmos RC, Van Baal GC, Vonk R, Wijkhuijs AJ, Kahn RS, Nolen WA, Drexhage HA. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch Gen Psychiatry. 2009 Sep;66(9):957-65. doi: 10.1001/archgenpsychiatry.2009.116.
- Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA. 2003 Sep 17;290(11):1517-9. doi: 10.1001/jama.290.11.1517. No abstract available. Erratum In: JAMA. 2004 Jan 14;291(2):186.
- Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978 Nov;133:429-35. doi: 10.1192/bjp.133.5.429.
- Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA, Lu J, Khan WI, Corthesy-Theulaz I, Cherbut C, Bergonzelli GE, Collins SM. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology. 2010 Dec;139(6):2102-2112.e1. doi: 10.1053/j.gastro.2010.06.063. Epub 2010 Jun 27.
- Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003 Mar;60(3):261-9. doi: 10.1001/archpsyc.60.3.261.
- Gitlin MJ, Mintz J, Sokolski K, Hammen C, Altshuler LL. Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery. J Clin Psychiatry. 2011 May;72(5):692-7. doi: 10.4088/JCP.09m05291gre. Epub 2010 Jun 29.
- Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck PE Jr, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003 Jun;64(6):680-90; quiz 738-9. doi: 10.4088/jcp.v64n0610.
- Post RM, Leverich GS, Nolen WA, Kupka RW, Altshuler LL, Frye MA, Suppes T, McElroy S, Keck P, Grunze H, Walden J; Stanley Foundation Bipolar Network. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord. 2003 Dec;5(6):396-406. doi: 10.1046/j.1399-5618.2003.00065.x.
- Joffe RT, MacQueen GM, Marriott M, Trevor Young L. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord. 2004 Feb;6(1):62-6. doi: 10.1046/j.1399-5618.2003.00091.x.
- Gaykema RP, Goehler LE, Lyte M. Brain response to cecal infection with Campylobacter jejuni: analysis with Fos immunohistochemistry. Brain Behav Immun. 2004 May;18(3):238-45. doi: 10.1016/j.bbi.2003.08.002.
- Goehler LE, Park SM, Opitz N, Lyte M, Gaykema RP. Campylobacter jejuni infection increases anxiety-like behavior in the holeboard: possible anatomical substrates for viscerosensory modulation of exploratory behavior. Brain Behav Immun. 2008 Mar;22(3):354-66. doi: 10.1016/j.bbi.2007.08.009. Epub 2007 Oct 24.
- Culligan EP, Hill C, Sleator RD. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009 Nov 23;1(1):19. doi: 10.1186/1757-4749-1-19.
- Verdu EF. Probiotics effects on gastrointestinal function: beyond the gut? Neurogastroenterol Motil. 2009 May;21(5):477-80. doi: 10.1111/j.1365-2982.2009.01297.x.
- Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009 Mar 1;29(5):508-18. doi: 10.1111/j.1365-2036.2008.03911.x. Epub 2008 Dec 2.
- Bailey MT, Coe CL. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol. 1999 Sep;35(2):146-55.
- Bailey MT, Lubach GR, Coe CL. Prenatal stress alters bacterial colonization of the gut in infant monkeys. J Pediatr Gastroenterol Nutr. 2004 Apr;38(4):414-21. doi: 10.1097/00005176-200404000-00009.
- Tannock GW, Savage DC. Influences of dietary and environmental stress on microbial populations in the murine gastrointestinal tract. Infect Immun. 1974 Mar;9(3):591-8. doi: 10.1128/iai.9.3.591-598.1974.
- Suzuki K, Harasawa R, Yoshitake Y, Mitsuoka T. Effects of crowding and heat stress on intestinal flora, body weight gain, and feed efficiency of growing rats and chicks. Nihon Juigaku Zasshi. 1983 Jun;45(3):331-8. doi: 10.1292/jvms1939.45.331. No abstract available.
- Goncharova GI, Liz'ko NN, Liannaia AM, Shilov VM, Spitsa TI. [Bifidobacterium flora status of cosmonauts before and after completing space flights]. Kosm Biol Aviakosm Med. 1981;15(3):14-8. Russian.
- Klooker TK, Braak B, Painter RC, de Rooij SR, van Elburg RM, van den Wijngaard RM, Roseboom TJ, Boeckxstaens GE. Exposure to severe wartime conditions in early life is associated with an increased risk of irritable bowel syndrome: a population-based cohort study. Am J Gastroenterol. 2009 Sep;104(9):2250-6. doi: 10.1038/ajg.2009.282. Epub 2009 Jun 9.
- Fitzgerald P, Cassidy Eugene M, Clarke G, Scully P, Barry S, Quigley Eamonn MM, Shanahan F, Cryan J, Dinan Timothy G. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil. 2008 Dec;20(12):1291-7. doi: 10.1111/j.1365-2982.2008.01195.x. Epub 2008 Sep 24.
- Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002 Apr;122(4):1140-56. doi: 10.1053/gast.2002.32392.
- Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther. 2003 Jan-Feb;10(1):61-7. doi: 10.1097/00045391-200301000-00014.
- Marks DM, Han C, Krulewicz S, Pae CU, Peindl K, Patkar AA, Masand PS. History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. Prim Care Companion J Clin Psychiatry. 2008;10(5):368-75. doi: 10.4088/pcc.v10n0504.
- Creed F, Ratcliffe J, Fernandes L, Palmer S, Rigby C, Tomenson B, Guthrie E, Read N, Thompson DG; North of England IBS Research Group. Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. Br J Psychiatry. 2005 Jun;186:507-15. doi: 10.1192/bjp.186.6.507.
- O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005 Mar;128(3):541-51. doi: 10.1053/j.gastro.2004.11.050.
- Hamilton-Miller JMT. Probiotics in the Management of Irritable Bowel Syndrome: A Review of Clinical Trials. Microbial Ecology in Health & Disease 2001;13:212-216
- Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003 Apr 1;17(7):895-904. doi: 10.1046/j.1365-2036.2003.01543.x.
- Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005 Oct;17(5):687-96. doi: 10.1111/j.1365-2982.2005.00695.x.
- Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005 Sep 1;22(5):387-94. doi: 10.1111/j.1365-2036.2005.02579.x.
- Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr. 2005 Dec;24(6):925-31. doi: 10.1016/j.clnu.2005.06.001. Epub 2005 Jul 27.
- Bauserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005 Aug;147(2):197-201. doi: 10.1016/j.jpeds.2005.05.015. Erratum In: J Pediatr. 2014 Oct;165(4):878. Bausserman, Melissa [corrected to Bauserman, Melissa].
- McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003 Jul;52(7):975-80. doi: 10.1136/gut.52.7.975.
- Duke K, Murphy S, Smith M. Probiotic performance in IBD is not uniform: a multi-strain comparison in the lymphocyte transfer model of enterocolitis. Gastroenterology. 2004;126:A283-A284.
- Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009 Aug;70(8):1078-90. doi: 10.4088/JCP.08r04505. Epub 2009 Jun 2.
- Spielberger CD. Manual for the State-Trait Anxiety Inventory. Corsini Encyclopedia of Psychology. 1. Palo Alto, CA: Consulting Psychologists Press; 1983
- Guy W. Global Impression Scale. ECDEU Assessment Manual for Psychopharmacology-Revised. 1976.
- Arbuckle R, Frye MA, Brecher M, Paulsson B, Rajagopalan K, Palmer S, Degl' Innocenti A. The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder. Psychiatry Res. 2009 Jan 30;165(1-2):163-74. doi: 10.1016/j.psychres.2007.11.018. Epub 2008 Nov 29.
- Bartram AK, Lynch MD, Stearns JC, Moreno-Hagelsieb G, Neufeld JD. Generation of multimillion-sequence 16S rRNA gene libraries from complex microbial communities by assembling paired-end illumina reads. Appl Environ Microbiol. 2011 Jun;77(11):3846-52. doi: 10.1128/AEM.02772-10. Epub 2011 Apr 1. Erratum In: Appl Environ Microbiol. 2011 Aug;77(15):5569.
- American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002 Apr;159(4 Suppl):1-50. No abstract available.
- Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003 Jun;17(2):149-73; discussion 147. doi: 10.1177/0269881103017002003.
- Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry. 2004 May;38(5):280-305. doi: 10.1080/j.1440-1614.2004.01356.x.
- Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young AH. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry. 2004 Apr;65(4):571-9. No abstract available.
- Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005 Jul;66(7):870-86. doi: 10.4088/jcp.v66n0710.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
安慰剂的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的